<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70553">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975441</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU 3 vs 2 LF ELIM PNG</org_study_id>
    <nct_id>NCT01975441</nct_id>
  </id_info>
  <brief_title>Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa</brief_title>
  <official_title>Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Case Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Case Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if a combination of 3 drugs used to treat the infection that cause
      lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in
      killing or sterilizing the adult worms compared to just 2 of the 3 drugs that usually given
      to treat this infection.  The three drugs used together are called albendazole (ALB),
      ivermectin (IVM) and diethylcarbamazine (DEC).  The usual treatment in Papua New Guinea
      (PNG) for lymphatic filariasis are DEC and ALB.  A combination of these 3 drugs has not been
      previously used to treat LF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will determine whether 1 or 2 annual treatments with the triple drug regimen of
      DEC/Iver/Alb is equally or more effective than repeated annual treatments with DEC/Alb in
      inducing sustained clearance of Mf in LF infected subjects previously determined to have
      &gt;100Mf/ml, indicative of a moderate to heavy infection.   Subjects will be treated and
      monitored in several common areas near study subject residences.

      There will be 3 treatment arms as follows:

        1. The comparator  (standard treatment) DEC 6 mg/kg + Alb 400 mg administered annually (at
           0, 12, and 24 months).

        2. DEC 6 mg/kg + Alb 400 mg given once

        3. DEC 6 mg/kg + Alb 400 mg + Iver 200 µg/kg administered once only at the beginning of
           the RCT (0 month).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with total clearance of in Wuchereria bancrofti (Wb) microfilaria (mf)</measure>
    <time_frame>at 36 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Lymphatic Filariasis</condition>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEC 6 mg/kg + Alb 400 mg x 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEC + ALB + IVM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylcarbamazine</intervention_name>
    <description>Diethylcarbamazine 6mg/kg</description>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_label>DEC 6 mg/kg + Alb 400 mg x 1</arm_group_label>
    <arm_group_label>DEC + ALB + IVM</arm_group_label>
    <other_name>DEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Albendazole 400mg</description>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_label>DEC 6 mg/kg + Alb 400 mg x 1</arm_group_label>
    <arm_group_label>DEC + ALB + IVM</arm_group_label>
    <other_name>ALB, Albenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Ivermectin 200 mcg/kg</description>
    <arm_group_label>DEC + ALB + IVM</arm_group_label>
    <other_name>IVM, Stromectol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18-65 years

          -  &gt;100mf/ml in finger stick blood samples

          -  Willing to give informed consent

        Exclusion Criteria:

          -  Prior treatment for LF within last 5 years

          -  Pregnant (do pregnancy test)

          -  Hemoglobin &lt; 7 g/dl

          -  permanent disability, serious medical illness that prevents or impedes study
             participation and/or comprehension

          -  AST/ALT and creatinine &gt; 1.5 upper limit of normal.

          -  Urine dipstick with glucose ≥ 2+ and/or protein ≥ 2+
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Siba, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Papua New Guinea Institution for Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher L King, MD, PhD</last_name>
    <phone>4402476904</phone>
    <email>cxk21@case.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James W Kazura, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Papua New Guinean Institute for Medical Research</name>
      <address>
        <city>Maprik</city>
        <state>East Sepik</state>
        <country>Papua New Guinea</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Suamani</last_name>
      <phone>+675 71066112</phone>
      <email>jsuamani@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Manasseh Baea</last_name>
      <phone>+675 73332320</phone>
      <email>manasseh.baea@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Papua New Guinea</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Case Medical Center</investigator_affiliation>
    <investigator_full_name>Christopher L. King, MD, PhD</investigator_full_name>
    <investigator_title>Professor/PI</investigator_title>
  </responsible_party>
  <keyword>Diethycarbamazine</keyword>
  <keyword>Albendazole</keyword>
  <keyword>Ivermectin</keyword>
  <keyword>Lymphatic filariasis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Elephantiasis, Filarial</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
    <mesh_term>Filariasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Diethylcarbamazine</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
